

## Case Report

### Methylmalonic Acidemia with Novel *MUT* Gene Mutations

Inusha Panigrahi, Savita Bhunwal, Harish Varma, and Simranjeet Singh

Department of Pediatrics, Advanced Pediatric Centre, PGIMER, Chandigarh, India

Correspondence: Inusha Panigrahi; inupan@yahoo.com

Methylmalonic acidemia (MMA) is a rare inherited metabolic disorder caused by deficiency of the enzyme methylmalonyl-CoA mutase. The disease is presented in early infancy by lethargy, vomiting, failure to thrive, encephalopathy and is deadly if left untreated. A 5-years old boy presented with recurrent episodes of fever, feeding problems, lethargy, from the age of 11 months, and poor weight gain. He was admitted and evaluated for metabolic causes and diagnosed as methylmalonic acidemia (MMA). He was treated with vit B12 and carnitine supplements and has been on follow-up for the last 3 years. Mutation analysis by next generation sequencing (NGS), supplemented with Sanger sequencing, revealed two novel variants in the *MUT* gene responsible for MMA in exon 5 and exon 3. Recently he developed dystonic movements including orofacial dyskinesia. Our results indicate the necessity of genetic testing if MMA is suspected; it would confirm the diagnosis, aid in selecting treatment options, and may enrich the panel of responsible gene variants.

## 1. Introduction

Methylmalonic acidemia (MMA) is a rare inherited metabolic disorder caused by deficiency of the enzyme methylmalonyl-CoA mutase. MMA presents with lethargy, acidosis, hypoglycemia/ hyperglycemia, ketosis, and recurrent episodes. MMA due to *MUT* gene mutations usually led to severe phenotype, and around 35–40% of cases are due to new mutations [1, 2]. There can be missense or nonmutations, deletions, insertions, and so on leading to clinical phenotype.

Variants of the *MUT* gene encoding the enzyme methylmalonyl-CoA mutase are responsible for about 60% of MMA cases; *mut0* and *mut-* phenotypes are caused by complete and partial enzyme deficiency, respectively. Variations in the *MMAA*, *MMAB*, *MMADHC*, and *MCEE* genes are required for normal functioning of methylmalonyl CoA mutase.

Finally, the novelty of the present MMA case should be introduced by stating that the patient had two previously unreported mutations in the *MUT* gene.

Here, we report the case of a 5-years old boy who presented with recurrent episodes of fever, feeding problems, lethargy, from the age of 11 months, and poor weight gain who was found to have two previously unreported mutations in the *MUT* gene.

## 2. Case Presentation

#### Commented [A 1]: Important:

1. As per the journal, units of measurement should be presented simply and concisely using System International (SI) units; please ensure that units are presented using the SI system at all instances.
2. References for some previously published data is missing. Please ensure that references are provided wherever required.
3. Informed consent from the patient is required and should be mentioned in the manuscript.

For more information, please refer to the guidelines at <https://www.hindawi.com/journals/crig/guidelines/>.

Commented [A 2]: As per the journal's guidelines, please provide email addresses of all the authors.

Formatted: Right: 0 cm, Space Before: 0 pt, Line spacing: single

Formatted: Font: Palatino Linotype, 11 pt

The child presented for the first time at the age of 11 months, with complaints of fever, vomiting, poor feeding, and lethargy. On examination he had pallor and tachypnea and was drowsy. Further evaluation was suggestive of high anion-gap metabolic acidosis with ketonuria (urine ketones3+) with normal electrolytes, blood sugar (94 mg/dl), vitamin B12, and homocysteine. Plasma ammonia was 118 units, and plasma lactate was 2.9 units. TMS was normal but urine GCMS revealed elevated 3-OH propionic acid [12.39 retention time (RT)] as well as elevated methyl malonic acid [16.92 RT, Suppl Figure 1, in Supplementary Material available online at <https://doi.org/10.1155/2017/8984951>]. Since then this child was on low protein diet, carnitine, biotin, thiamine, and vitamin B12 injections. Child was thereafter admitted on multiple occasions (7 times) with acute decompensation and managed as per protocol. Mutational analysis was sent for MMA which showed single heterozygous missense variant c.976 A>G (p.Arg326Gly) in exon 5 of *MUT* gene (genomic coordinates: chr 6: 49421405) as a variant of uncertain significance. Chromosomal microarray analysis done did not reveal any major deletion or duplication which could disrupt the gene. Since exon 3 and exon 6 were not adequately covered by NGS, further evaluation by Sanger sequencing for targeted exons was done and a 2nd mutation in exon 3 c.753 G>A (p.=) was identified. The variants were found to be damaging on SIFT database score (Suppl data). They were also predicted to be deleterious on Polyphen-2 and Mutation Taster and not found in the ExAC database. MRI brain done at the age of 4 years was showing multifocal cystic encephalomalacic changes with surrounding gliosis in deep white matter predominantly in frontoparietal regions (Figure 1). In latest admission child was found to have fresh neurological findings in the form of perioral tremors, generalised hypertonia, and generalised dystonia with clonus with exaggerated deep tendon reflexes. He was treated with intravenous dextrose and sodium bicarbonate and was continued on carnitine and injection of vitamin B12. Plasma ammonia was 18 units and lactate level was 4.9 units. MRI brain was repeated and revealed bilateral basal ganglia hyperintensities suggestive of metabolic stroke. After the subsidence of acute crisis he was discharged on carnitine, injection of vitamin B12, and trihexyphenidyl. Parents were counseled regarding prognosis and for prenatal diagnosis next pregnancy.



FIGURE 1: The MRI brain in the child with *MUT*-related MMA showing predominant frontoparietal abnormalities in form of encephalomalacia and gliosis.

### 3. Discussion

The advent of NGS technology has enabled better characterization of mutations in several populations. In this study, we used NGS and Sanger sequencing to identify mutations in the genes linked to MMA development and revealed two novel variants of the *MUT* gene. In a Saudi study on 60 patients of MMA, nonsense, missense, and frameshift mutations were detected across the *MUT* gene [3]. Another study in 43 Chinese patients identified 8 recurrent mutations and 10 novel mutations [4]. A previous Indian study in 15 patients of clinically diagnosed MMA identified one novel exon 12 mutation in *MUT* gene with predicted pathogenicity. Here, we identified two novel variants, one in exon 3 and another in exon 5 of the *MUT* gene. Both were labelled as variants of unknown significance (VUS). The exon 3 variant is a synonymous variant, and a different nucleotide change c.753 G>C (p.Lys251Asn) has been reported earlier in ClinVar. Some synonymous variants can also affect the splicing or protein function and lead to clinical phenotypes. The identified exon 5 variant is new, but another close variant c.977 G>A (p.Arg326Lys) has been reported in ClinVar. The variants were found to be deleterious on bioinformatic analysis and were not found in ExAC database. Both variants identified in present case possibly explain the phenotype of MMA in the child. *MUT*-related MMA has poor prognosis in most cases. Specialised diet and supplements may not improve outcomes, even if diagnosed early. Early recognition and appropriate treatment of acute crises are necessary. Metabolic stroke can sometimes occur in the absence of acute metabolic decompensation, so meticulous neurological examination at each visit is useful. e options for therapy include early liver transplantation [5] and possibly gene therapy in the future. Genetic counseling and prenatal diagnosis help these families in making reproductive decisions.

Formatted: Space Before: 0 pt

Formatted: Font: Italic

Formatted: Font: Italic

Formatted: Font: Italic

Formatted: Font: Italic

### Conflicts of Interest

The authors declare that ~~there is they have~~ no conflicts of interest ~~regarding the publication of~~ ~~this article.~~

### Acknowledgments

The authors would like to acknowledge Dhiti Omics Tech- nologies Pvt Ltd for help in mutation ~~analysis.~~

### References

- [1] K. Splinter, A.-K. Niemi, R. Cox et al., "Impaired health-related quality of life in children and families affected by methyl- malonic acidemia," *Journal of Genetic Counseling*, vol. 25, no. 5, pp. 936–944, 2016.
- [2] A. R. R. Devi and S. M. Naushad, "Targeted exome sequencing for the identification of complementation groups in methyl- malonic aciduria: a south Indian experience," *Clinical Biochem-istry*, vol. 50, no. 1-2, pp. 68–72, 2017.
- [3] F. Imtiaz, B. M. Al-Mubarak, A. Al-Mostafa et al., "Spectrum of mutations in 60 saudi patients with mut methylmalonic acidemia," *JIMD Reports*, vol. 29, pp. 39–46, 2016.
- [4] ~~L. S. Han LS, Z. Huang Z, F. Han F, et al., Ye J, Qiu WJ, Zhang HW, Wang Y, Gong ZW, Gu XF.~~ "Clinical features and MUT gene mutation spectrum in Chinese patients with isolated methylmalonic acidemia: identification of ten novel allelic variants," *World Journal of Pediatrics*, ~~vol. 2015 Nov 1, no. 11(4), pp. 358–365, 2015.~~
- [5] M. Spada, P. L. Calvo, A. Brunati et al., "Liver transplantation in severe methylmalonic acidemia: the sooner, the better," *Journal of Pediatrics*, ~~vol. 2015;167, pp. 1173, 2015.~~

**Commented [A3]:** The journal's preferred statement has been used.

**Formatted:** Space Before: 0 pt, Line spacing: single

**Commented [A4]:** As per the guidelines, a section titled "Supplementary Materials" should be included before the reference list with a concise description for each supplementary material file, if relevant. Supplementary materials are not modified by the journal's production team. Authors are responsible for providing the final supplementary materials files that will be published along with the article.

**Formatted:** Font color: Custom Color(RGB(43,42,41))

**Formatted:** Space Before: 0 pt

**Formatted:** Space Before: 0 pt, Line spacing: single

**Formatted:** Indent: Hanging: 0.5 cm, Space Before: 0 pt, Line spacing: single

**Formatted:** Font: Italic

**Formatted:** Font: Italic